Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.



Status:Archived
Conditions:Arthritis, Rheumatoid Arthritis
Therapuetic Areas:Rheumatology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:September 2010
End Date:February 2013

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

(OSKIRA-2): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients With an Inadequate Response to DMARDs


The purpose of the study is to evaluate the effectiveness of two dosing regimens of
fostamatinib compared to placebo, in patients with rheumatoid arthritis (RA) who are taking
disease modifying anti-rheumatic drug (DMARD) but not responding. The study will last for 1
year.



We found this trial at
2
sites
Clinical Trial Facility in Birmingham Alabama
Birmingham, Alabama
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Clinical Trial Facility in New Haven Connecticut
New Haven, Connecticut
?
mi
from
New Haven, CT
Click here to add this to my saved trials